Literature DB >> 16867222

FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells.

Jane Reiland1, Doty Kempf, Madhuchhanda Roy, Yvonne Denkins, Dario Marchetti.   

Abstract

Heparanase (HPSE) and fibroblast growth factor-2 (FGF2) are critical regulators of melanoma angiogenesis and metastasis. Elevated HPSE expression contributes to melanoma progression; however, further augmentation of HPSE presence can inhibit tumorigenicity. HPSE enzymatically cleaves heparan sulfate glycosaminoglycan chains (HS) from proteoglycans. HS act as both low-affinity FGF2 receptors and coreceptors in the formation of high-affinity FGF2 receptors. We have investigated HPSE's ability to modulate FGF2 activity through HS remodeling. Extensive HPSE degradation of human metastatic melanoma cells (70W) inhibited FGF2 binding. Unexpectedly, treatment of 70W cells with low HPSE concentrations enhanced FGF2 binding. In addition, HPSE-unexposed cells did not phosphorylate extracellular signal-related kinase (ERK) or focal adhesion kinase (FAK) in response to FGF2. Conversely, in cells treated with HPSE, FGF2 stimulated ERK and FAK phosphorylation. Secondly, the presence of soluble HPSE-degraded HS enhanced FGF2 binding and ERK phosphorylation at low HS concentrations. Higher concentrations of soluble HS inhibited FGF2 binding, but FGF2 signaling through ERK remained enhanced. Soluble HS were unable to support FGF2-stimulated FAK phosphorylation irrespective of HPSE treatment. Finally, cell exposure to HPSE or to HPSE-degraded HS modulated FGF2-induced angiogenesis in melanoma. In conclusion, these effects suggest relevant mechanisms for the HPSE modulation of melanoma growth factor responsiveness and tumorigenicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16867222      PMCID: PMC1601937          DOI: 10.1593/neo.06244

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  57 in total

Review 1.  Heparan sulfate proteoglycans: intricate molecules with intriguing functions.

Authors:  R V Iozzo
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

2.  Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation.

Authors:  A C Rapraeger; A Krufka; B B Olwin
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

3.  Antisense-mediated suppression of Heparanase gene inhibits melanoma cell invasion.

Authors:  Madhuchhanda Roy; Jane Reiland; Brian P Murry; Vladimir Chouljenko; Konstantin G Kousoulas; Dario Marchetti
Journal:  Neoplasia       Date:  2005-03       Impact factor: 5.715

Review 4.  Heparan sulfate proteoglycans in invasion and metastasis.

Authors:  R D Sanderson
Journal:  Semin Cell Dev Biol       Date:  2001-04       Impact factor: 7.727

5.  Processing of macromolecular heparin by heparanase.

Authors:  Feng Gong; Per Jemth; Martha L Escobar Galvis; Israel Vlodavsky; Alan Horner; Ulf Lindahl; Jin-ping Li
Journal:  J Biol Chem       Date:  2003-07-01       Impact factor: 5.157

6.  PDGF and FGF induce focal adhesion kinase (FAK) phosphorylation at Ser-910: dissociation from Tyr-397 phosphorylation and requirement for ERK activation.

Authors:  Isabel Hunger-Glaser; Robert S Fan; Eduardo Perez-Salazar; Enrique Rozengurt
Journal:  J Cell Physiol       Date:  2004-08       Impact factor: 6.384

7.  Focal adhesion kinase activated by beta(4) integrin ligation to mCLCA1 mediates early metastatic growth.

Authors:  Mossaad Abdel-Ghany; Hung-Chi Cheng; Randolph C Elble; Bendicht U Pauli
Journal:  J Biol Chem       Date:  2002-07-10       Impact factor: 5.157

8.  Heparan sulfate regulates targeting of syndecan-1 to a functional domain on the cell surface.

Authors:  Yang Yang; Magne Børset; J Kevin Langford; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2003-02-03       Impact factor: 5.157

9.  Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequence.

Authors:  Yukihiko Okada; Shuhei Yamada; Minako Toyoshima; Jian Dong; Motowo Nakajima; Kazuyuki Sugahara
Journal:  J Biol Chem       Date:  2002-09-03       Impact factor: 5.157

10.  Heparan sulphate glycosaminoglycans derived from endothelial cells and smooth muscle cells differentially modulate fibroblast growth factor-2 biological activity through fibroblast growth factor receptor-1.

Authors:  David Berry; Zachary Shriver; Barbara Natke; Chi-Pong Kwan; Ganesh Venkataraman; Ram Sasisekharan
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

View more
  33 in total

1.  Gekko-sulfated glycopeptide inhibits tumor angiogenesis by targeting basic fibroblast growth factor.

Authors:  Shuang-Xia Zhang; Cong Zhu; Yi Ba; Dan Chen; Xing-Long Zhou; Rui Cao; Li-Ping Wang; Yuan Ren; Xiong-Zhi Wu
Journal:  J Biol Chem       Date:  2012-02-25       Impact factor: 5.157

Review 2.  Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.

Authors:  Rajendra Gharbaran
Journal:  Tumour Biol       Date:  2016-06-18

3.  Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells.

Authors:  Valentina Masola; Giovanni Gambaro; Elena Tibaldi; Anna Maria Brunati; Alessandra Gastaldello; Angela D'Angelo; Maurizio Onisto; Antonio Lupo
Journal:  J Biol Chem       Date:  2011-11-18       Impact factor: 5.157

4.  Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.

Authors:  Anurag Purushothaman; Ligong Chen; Yang Yang; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2008-09-23       Impact factor: 5.157

Review 5.  Heparanase and hepatocellular carcinoma: promoter or inhibitor?

Authors:  Shuo Dong; Xiong-Zhi Wu
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

6.  HIP/RPL29 antagonizes VEGF and FGF2 stimulated angiogenesis by interfering with HS-dependent responses.

Authors:  Sonia D'Souza; Weidong Yang; Dario Marchetti; Caroline Muir; Mary C Farach-Carson; Daniel D Carson
Journal:  J Cell Biochem       Date:  2008-12-01       Impact factor: 4.429

7.  Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression.

Authors:  Jianghua Wang; Wendong Yu; Yi Cai; Chengxi Ren; Michael M Ittmann
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

8.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

Review 9.  The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.

Authors:  Vishnu C Ramani; Anurag Purushothaman; Mark D Stewart; Camilla A Thompson; Israel Vlodavsky; Jessie L-S Au; Ralph D Sanderson
Journal:  FEBS J       Date:  2013-03-04       Impact factor: 5.542

10.  Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells.

Authors:  Danilo Millimaggi; Marianna Mari; Sandra D'Ascenzo; Eleonora Carosa; Emmanuele Angelo Jannini; Stanley Zucker; Gaspare Carta; Antonio Pavan; Vincenza Dolo
Journal:  Neoplasia       Date:  2007-04       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.